Basit öğe kaydını göster

dc.contributor.authorGoldberg, Eugene P.
dc.contributor.authorCelikoglu, Firuz
dc.contributor.authorCelikoglu, Seyhan I.
dc.date.accessioned2021-03-05T13:37:19Z
dc.date.available2021-03-05T13:37:19Z
dc.date.issued2008
dc.identifier.citationCelikoglu F., Celikoglu S. I. , Goldberg E. P. , "Bronchoscopic intratumoral chemotherapy of lung cancer", LUNG CANCER, cilt.61, ss.1-12, 2008
dc.identifier.issn0169-5002
dc.identifier.othervv_1032021
dc.identifier.otherav_b30e27c1-897d-4a8c-a2b0-525e9c8453da
dc.identifier.urihttp://hdl.handle.net/20.500.12627/119283
dc.identifier.urihttps://doi.org/10.1016/j.lungcan.2008.03.009
dc.description.abstractDescribed in this review is a therapeutic procedure for localized chemotherapy of lung cancer by bronchoscopic intervention. This procedure involves the intratumoral. injection of one or several conventional cytotoxic drugs directly into tumor tissue through a flexible bronchoscope by means of an ordinary needle-catheter, and is termed "endobronchial intratumoral. chemotherapy" (EITC). Intratumoral (IT) chemotherapy should not be considered merely an ablation technique for treatment of endobronchial. tumor bulk such as other ablative endoscopic procedures. EITC rather affords a significant specific chemotherapeutic effect on malignant cells through the localized action of cytotoxic drugs. Although superficialty similar to ablative methods such as brachytherapy and photodynamic therapy, EITC provides the multiple benefits of rapid initial eradication of tumor burden inside the airway lumen plus intratumoral delivery of cytotoxic drugs as a toco-regional neoadjuvant therapeutic modality prior to irradiation or surgery. It is localized chemotherapy which differs from intravenous chemotherapy by the route of delivery and mode of action. The manifold advantages of the EITC intratumoral injection procedure include (1) precise delivery of cancer drugs to and within the tumor, (2) complete perfusion of the lesion, (3) dramatically higher intratumor drug concentrations than possible by systemic drug delivery, and (4) virtually none of the toxic side effects which normally occur with conventional systemic chemotherapy.
dc.language.isoeng
dc.subjectGöğüs Hastalıkları ve Allerji
dc.subjectİç Hastalıkları
dc.subjectOnkoloji
dc.subjectSağlık Bilimleri
dc.subjectDahili Tıp Bilimleri
dc.subjectTıp
dc.subjectSOLUNUM SİSTEMİ
dc.subjectKlinik Tıp (MED)
dc.subjectKlinik Tıp
dc.subjectONKOLOJİ
dc.titleBronchoscopic intratumoral chemotherapy of lung cancer
dc.typeMakale
dc.relation.journalLUNG CANCER
dc.contributor.departmentState University System of Florida , ,
dc.identifier.volume61
dc.identifier.issue1
dc.identifier.startpage1
dc.identifier.endpage12
dc.contributor.firstauthorID188773


Bu öğenin dosyaları:

DosyalarBoyutBiçimGöster

Bu öğe ile ilişkili dosya yok.

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster